Coherus Bioscien Stock Price, News & Analysis

Coherus BioSciences, Inc. (Nasdaq: CHRS) will release its third quarter 2020 financial results on November 5, 2020, after market close. A conference call will follow at 4:30 p.m. EST to discuss the results and provide business updates. Investors can access the financial results on Coherus' website after the announcement. The company focuses on developing and commercializing biosimilars, including its product UDENYCA® and additional candidates like CHS-1420 and CHS-2020, targeting various chronic diseases.

Coherus BioSciences, Inc. (Nasdaq: CHRS) announced on October 16, 2020, that its compensation committee granted stock options and restricted stock units to newly hired executives. The newly appointed Executive Vice President received an option for 150,000 shares, while a Senior Vice President received options for 100,000 shares. Two Vice Presidents were granted options for 45,000 shares each. Additionally, seven non-officer employees were granted a total of 92,000 shares. All options have an exercise price of $18.09, the closing price on the grant date. Coherus specializes in biosimilar therapeutics.

Coherus BioSciences announced on September 18, 2020, that it granted stock options to new employees, totaling 118,000 shares for non-officer staff and 45,000 shares for a Vice President. The exercise price is set at $19.07, the closing price on the grant date, September 17, 2020. This action is part of the 2016 Employment Commencement Incentive Plan to attract new talent. Coherus specializes in biosimilar therapeutics and has commercialized UDENYCA (pegfilgrastim-cbqv), while advancing several late-stage biosimilar candidates.

On August 19, 2020, Coherus BioSciences (Nasdaq: CHRS) granted stock options amounting to 64,000 shares to seven newly hired non-officer employees. The exercise price for these options was set at $19.85, reflecting the closing price on the grant date. This action was part of the Company's 2016 Employment Commencement Incentive Plan, which aims to attract new talent. Coherus BioSciences focuses on developing and commercializing biosimilar therapeutics, including UDENYCA®, and is advancing several late-stage clinical products in the biosimilar market.

Coherus BioSciences reported strong second-quarter 2020 results with net sales of $135.7 million and net income of $59.0 million, or $0.70 per diluted share. Non-GAAP net income was $68.3 million, representing $0.81 per diluted share. The company boosted cash reserves to $456.5 million, largely from operating cash flow and proceeds from convertible debt. R&D expenses increased to $26.2 million amid preparations for biosimilar applications. Full-year guidance for combined R&D and SG&A expenses is maintained at $285-$310 million.

Coherus BioSciences (CHRS) has appointed Kimberly Tzoumakas, J.D. to its Board of Directors, effective July 30, 2020. Tzoumakas, previously CEO of 21st Century Oncology, brings over 20 years of healthcare leadership experience. Her appointment comes as Coherus aims to commercialize six biosimilars by 2025. Tzoumakas expressed enthusiasm about the opportunities for biosimilars to enhance value for various stakeholders in the healthcare system.

On July 17, 2020, Coherus BioSciences (CHRS) announced the grant of stock options totaling 178,000 shares to new employees and an Executive Vice President, with an exercise price of $18.30. This action was taken under the 2016 Employment Commencement Incentive Plan, aimed at attracting talent to the company. Coherus is a prominent player in the biosimilar market, focusing on therapies for chronic diseases and reducing healthcare costs. The company commercializes UDENYCA® in the U.S. and is advancing several biosimilar products toward commercialization.

Coherus BioSciences (CHRS) announced on June 19, 2020, the grant of stock options to employees as part of its 2016 Employment Commencement Incentive Plan. A total of 93,000 shares were granted to seven new non-officer employees, while an Executive Vice President received options for 125,000 shares, and a Vice President was granted options for 35,000 shares plus 10,000 restricted stock units. All options have a per share exercise price of $16.98, equal to the closing price on the grant date. Coherus is focused on biosimilars, including UDENYCA®, and has several late-stage and early-stage clinical products in development.

Coherus BioSciences (CHRS) reported first-quarter 2020 net sales of $116.2 million, a significant increase from $37.1 million in the previous year. The company achieved a net income of $35.6 million ($0.48 per share) and a non-GAAP net income of $49.8 million ($0.67 per share). The gross profit margin rose to 94%. Cash and equivalents totaled $193.3 million. Coherus entered into a licensing agreement with Innovent for a biosimilar of Avastin, enhancing its oncology pipeline. R&D and SG&A expenses are projected to be $285-$310 million for the fiscal year.